Stock Research for ACRX

ACRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACRX Stock Chart & Research Data

The ACRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACRX Due diligence Resources & Stock Charts

The ACRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACRX Detailed Price Forecast - CNN Money CNN View ACRX Detailed Summary - Google Finance
Yahoo View ACRX Detailed Summary - Yahoo! Finance Zacks View ACRX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ACRX Trends & Analysis - Trade-Ideas Barrons View ACRX Major Holders - Barrons
NASDAQ View ACRX Call Transcripts - NASDAQ Seeking View ACRX Breaking News & Analysis - Seeking Alpha
Spotlight View ACRX Annual Report - CompanySpotlight.com OTC Report View ACRX OTC Short Report - OTCShortReport.com
TradeKing View ACRX Fundamentals - TradeKing Charts View ACRX SEC Filings - Bar Chart
WSJ View Historical Prices for ACRX - The WSJ Morningstar View Performance/Total Return for ACRX - Morningstar
MarketWatch View the Analyst Estimates for ACRX - MarketWatch CNBC View the Earnings History for ACRX - CNBC
StockMarketWatch View the ACRX Earnings - StockMarketWatch MacroAxis View ACRX Buy or Sell Recommendations - MacroAxis
Bullish View the ACRX Bullish Patterns - American Bulls Short Pains View ACRX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ACRX Stock Mentions - StockTwits PennyStocks View ACRX Stock Mentions - PennyStockTweets
Twitter View ACRX Stock Mentions - Twitter Invest Hub View ACRX Investment Forum News - Investor Hub
Yahoo View ACRX Stock Mentions - Yahoo! Message Board Seeking Alpha View ACRX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ACRX - SECform4.com Insider Cow View Insider Transactions for ACRX - Insider Cow
CNBC View ACRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACRX - OTC Markets
Yahoo View Insider Transactions for ACRX - Yahoo! Finance NASDAQ View Institutional Holdings for ACRX - NASDAQ


Stock Charts

FinViz View ACRX Stock Insight & Charts - FinViz.com StockCharts View ACRX Investment Charts - StockCharts.com
BarChart View ACRX Stock Overview & Charts - BarChart Trading View View ACRX User Generated Charts - Trading View


Latest Financial News for ACRX

Blog Exposure - AcelRx Pharma Completes the Human Factors Study for DSUVIA
Posted on Wednesday April 18, 2018

LONDON, UK / ACCESSWIRE / April 18, 2018 / Active-Investors.com has just released a free research report on AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) ("AcelRx").If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ACRX as the Company's latest news hit the wire. On April 16, 2018, the specialty pharmaceutical Company, which is focused on the development and commercialization of innovative therapies for the treatment of acute pain, declared the successful completion of the human factor study to validate the effectiveness of the revised DSUVIA directions for use (DFU).


AcelRx Pharmaceuticals Announces Publication Concluding that Sublingual Sufentanil Tablets Provide the Opportunity to Non-Invasively and Rapidly Treat Moderate-To-Severe Acute Pain in a Monitored Setting
Posted on Wednesday April 18, 2018

REDWOOD CITY, Calif. , April 18, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...


AcelRx Announces Completion of the Human Factors Study for DSUVIA and Confirms Plans to Resubmit NDA in Q2 2018
Posted on Monday April 16, 2018

REDWOOD CITY, Calif. , April 16, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx or the Company), a specialty pharmaceutical company focused on innovative therapies for use in ...


AcelRx Announces Publication Analyzing the Cost of Administering IV Morphine for Acute Pain in Emergency Departments in Europe
Posted on Wednesday April 11, 2018

REDWOOD CITY, Calif., April 11, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported the publication of a report commissioned by AcelRx analyzing the economic burden associated with administration of intravenous (IV) morphine for acute pain in the emergency department (ED) in the peer-reviewed journal Drugs in Context. This manuscript reports on the results of a micro-costing analysis to estimate the burden of IV administration of morphine in five key European countries based on a literature review.


Enter a stock symbol to view the stock details.